QGEN
QIAGEN NV
NYSE · Healthcare · Medical - Diagnostics & Research · NL
$50.69
+0.61%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$50.76
From 52W high−8.94%
Volume1.25M
Market cap$10.47B
P/E (TTM)26.0x
P/S (TTM)5.0x
Div yield5.45%
Key dataNov 4, 2026
Open
$50.76
From 52W high
−8.94%
Volume
1.25M
Market cap
$10.47B
ValuationView details →
P/E (Fwd)
20.0x
EV/EBITDA
16.1x
P/E (TTM)
26.0x
RSI (14)
74.4
MomentumView details →
1D Return
+0.61%
YTD Return
+7.29%
SummaryUpdated Jun 1, 2026
QIAGEN N.V. (NASDAQ:QGEN) is a Netherlands-based multinational biotechnology company founded in 1986 that specializes in molecular diagnostics and life sciences research technologies. Originally established as a spin-off from the University of Düsseldorf, QIAGEN went public in 1996 and has grown through both organic expansion and strategic acquisitions to become a leading provider of sample preparation and molecular testing solutions. The company serves customers across molecular diagnostics, academic research, pharmaceutical development, and applied testing markets worldwide, with operations spanning over 35 countries and headquarters in Venlo, the Netherlands.
Similar companies
Latest newsMore news →
EQT AB acquired German diagnostics group QIAGEN N.V. in a €10.8 billion deal.14d agoQIAGEN reported preliminary third-quarter 2026 net sales of $548 million and adjusted diluted EPS of $0.65, both unchanged at constant exchange rates.14d agoQIAGEN and EQT Private Equity Co LLC announced an agreement for Crown NL Bidco to make a voluntary all-cash public takeover offer for all outstanding QIAGEN shares at €46.50 per share.14d ago